FDA approves Genzyme-Isis homozygous familial hypercholesterolemia therapy
The regulatory agency approved Kynamro 200mg subcutaneous injection per week as an added therapy to lipid-lowering medications and diet in HoFH patients. Kynamro will reduce low density lipoprotein-cholesterol
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.